Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1121-1130 Newer>

Bio-IT World April 16, 2004 Mark Uehling	PDAs and Clinical Trials PalmOne's director of healthcare sales explains why clinical trials are driving sales of handheld devices.
Bio-IT World April 16, 2004 Kevin Davies	The Matrix Revolutions Serenex, a company dedicated to drug discovery, uses a proprietary matrix, or affinity media, to bind purine-binding protiens - a process that could transform the drug discovery business.
Bio-IT World April 16, 2004 Malorye Branca	Finding the Perfect Fit Fragment-based drug discovery is unique and effective.
Bio-IT World April 16, 2004 Davic Hardison	The Business Case for Content Management Innovations are allowing bioscience companies to re-address how they manage content and data.
Bio-IT World April 16, 2004 Bill Van Etten	Zero Chances to Go Wrong Zeroconf is an Internet Engineering Task Force working group chartered to automate the configuration and discovery of computers, devices, and services on IP networks.
Bio-IT World April 16, 2004 Robert Frederickson	Trial Separations Protein separation through the digital ProteomeChip microchip takes merely minutes, resulting in significantly increased productivity.
Bio-IT World April 16, 2004	Best of the Best, Sir The FDA wants to change its ways and share its accumulated wisdom as part of a focused attack on costly, unpredictable product development.
The Motley Fool April 16, 2004 Charly Travers	Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out.
The Motley Fool April 16, 2004 Bill Mann	Stryker Hits It Again Stryker, the medical device company, reported year-over-year gains in revenues of 22%, with sales just over $1 billion. Earnings were even better: Stryker topped off last year's results by more than 30%.
BusinessWeek April 26, 2004 Gene Marcial	Cytogen Sharpens A New Cancer Weapon Cytogen, whose products help diagnose and treat cancer, could get a Food & Drug Administration O.K. by midyear for its new Combidex - a magnetic resonance imaging agent that helps radiologists tell cancerous from benign lymph nodes.
<Older 1121-1130 Newer> Return to current articles.